ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2959

Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up

Fatma Alibaz-Oner1, Emrah Karatay2, Belgin Aldag1, I.Nuri Akpınar2, Tulin Ergun3 and Haner Direskeneli4, 1Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 2Radiology, Marmara University, School of Medicine, Istanbul, Turkey, 3Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Major organ involvement, especially in young males, is one of the main causes of mortality and morbidity in Behcet’s Disease (BD). However, the prognosis and predictors of major organ involvement is unsufficiently studied. We aimed to follow young, male BD patients which have the highest risk for major organ involvement prospectively.

Methods: Thirty-six male patients with BD consecutively consulted in the Outpatient Clinics of Marmara University, 35 males with ankylosing spondylitis(AS),36 healthy males were included in the study. Bilateral upper and lower extremity venous doppler ultrasonography(US) and brachial and carotid arterial US (for assessing endothelial dysfunction) were performed in baseline visit for all groups and in the first year follow-up visit for BD patients. Patients with BD were assessed prospectively with 3-6 months intervals and in any urgent visit.

Results:  At baseline, the mean disease duration was 3.3 years in patients with BD. The rate of venous insufficiency was higher in male BD patients without vascular events, compared to healthy controls (BD vs HC: 30.5% vs 0%) and similar to patients with AS (BD vs AS. 30.5% vs 32%). Markers of endothelial dysfunction (FMD and NID) were similar between BD patients and healthy controls, however CIMT (Carotid intima media thickness) was significantly higher in BD (0.54 mm vs 0.47 mm, p=0.033). The mean follow-up duration was 44.6 months. Major organ involvement developed in 4 (11%, 3 vascular and 1 ocular involvement) patients during follow-up. All of them were in the first 2 years of follow-up. Immunsuppresive (IS) therapy was required in 22% (n=8) of patients, due to major organ involvement in 4 (11%) and refractory mucocutaneous symptoms in other four (11%) patients. In the first year follow-up visit, endothelial functions and CIMT were observed to be significantly improved compared to baseline (Baseline vs Follow-up: 6.8±4 vs 10.9±4.5, p=0.003 for FMD, 0.55±0.13 vs 0.47±0.1 for CIMT, p=0.004). The patients requiring IS treatment in the follow-up had significantly lower FMD at baseline compared to the rest of the group (4.4 vs 8.5, p=0.005).

Conclusion: Our study demonstrated a lower incidence of major vascular events in male BD patients during prospective follow-up compared to historic controls in the literature. However, our results confirmed an early onset of major organ involvement and IS use in the first year of disease follow-up. The decreased rate of baseline FMD in patients with later IS requirement suggest that FMD can be a predictor for major organ involvement in BD. Table 1: Clinical charecteristic of patients developing immunosuppressive need during follow-up.

IS onset during follow-up. Reason for IS use Age Disease duration when IS started IS agent
Patient 1 1.month Pulmonary aneurysm 35 1 year Azatioprine
Patient 2 7.month Refractory OU 25 5 years Cyclosporine
Patient 3 6. month Deep venous thrombosis 38 10 years Azatioprine
Patient 4 10. month Uveitis 20 5 years Azatioprine
Patient 5 9. month Refractory OU 28 7 years Azatioprine
Patient 6 13. month Refractory OU 23 6 years Cyclosporine
Patient 7 9. month Refractory EN 35 1 years Azatioprine
Patient 8 8. month Deep venous thrombosis 23 1 years Azatioprine

IS: Immunosuppressive, OU: Oral ulcer, EN: ertyhema nodosum


Disclosure: F. Alibaz-Oner, None; E. Karatay, None; B. Aldag, None; I. N. Akpınar, None; T. Ergun, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Alibaz-Oner F, Karatay E, Aldag B, Akpınar IN, Ergun T, Direskeneli H. Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/baseline-endothelial-dysfunction-might-predict-immunosuppressive-need-in-young-male-behcets-patients-with-early-disease-a-prospective-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-endothelial-dysfunction-might-predict-immunosuppressive-need-in-young-male-behcets-patients-with-early-disease-a-prospective-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology